A National Survey Exploring Dementia Diagnostics and Care Provisions in Primary Care in England
- 1Queen Mary University of London
Abstract
BackgroundThe 10 Year Health Plan for England indicates governmental intention to shift care from hospital to community. Disease Modifying Treatments (DMTs) and biomarker tests for dementia will likely be introduced, with potentially significant impacts on community care, particularly general practice.
AimTo explore dementia diagnosis, post diagnostic support and expectations around future care in primary care settings.
Design and SettingCodesigned survey with general practitioners (GPs), policy researchers, carers and people with lived experience. One GP per practice invited from five of Englands Integrated Care Boards (ICBs).
MethodsInductive content analysis for qualitative responses and non-weighted means calculated for quantitative answers. Findings contextualised using national data.
ResultsBetween September and December 2025, 80/1094 (7.3%) eligible practices participated (80 GPs). Most, (79/80, 98.8%) used cognitive assessments and 100% (80/80) blood tests to support dementia diagnosis, with 27/70 (39.7%) able to order brain scans directly. GPs primarily conducted annual physical, mental or care plan reviews for people with known dementia. Respondents considered it unlikely (47/80, 58.8%) they would formally diagnose dementia or assess (50/80, 62.3%) for DMT eligibility in the next five years. GPs considered it somewhat/most likely (54/80, 67.5%) they could offer blood biomarker tests and continue established DMT prescribing or monitoring (61/80, 76.3%). Resource, capacity and training needs were perceived barriers.
ConclusionGPs are the first point of contact for accessing a dementia diagnosis in England. Accommodating novel diagnostic tools and treatments requires a reimagining of the relationship between primary, secondary and social care to address GP reported constraints.
Related
- A national ecosystem for long-read genome sequencing: Integrating population genomics and rare disease diagnostics in Sweden
- Alcohol exclusion provisions and alcohol‐related insurance claim denials in the United States: A narrative review
- Mini‐Mental State Examination trajectories across dementia subtypes in the Swedish Registry for Cognitive/Dementia Disorders and U.S. National Alzheimer's Coordinating Center
- “It absolutely enlarged my world”: Exploring in-person and virtual performing arts programming for dementia care dyads
- Exploring caregivers’ perspectives and anticipated acceptance of hepatitis B birth-dose vaccination before the national introduction in Sierra Leone: a qualitative study
BibTeX
@misc{darby2026national,
title = {{A National Survey Exploring Dementia Diagnostics and Care Provisions in Primary Care in England}},
author = {A. Darby and J. Shaw and C. Cooper and N. Chemas and C. R. Marshall and N. Mukadam and K. Smith and R. Khan and S. Banerjee and G. Rait},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.11.26362825},
url = {https://www.medrxiv.org/content/10.64898/2026.09.11.26362825v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - A National Survey Exploring Dementia Diagnostics and Care Provisions in Primary Care in England
AU - A. Darby
AU - J. Shaw
AU - C. Cooper
AU - N. Chemas
AU - C. R. Marshall
AU - N. Mukadam
AU - K. Smith
AU - R. Khan
AU - S. Banerjee
AU - G. Rait
PY - 2026
DA - 2026/09/11
PB - medRxiv
DO - 10.64898/2026.09.11.26362825
UR - https://www.medrxiv.org/content/10.64898/2026.09.11.26362825v1
AB - BackgroundThe 10 Year Health Plan for England indicates governmental intention to shift care from hospital to community. Disease Modifying Treatments (DMTs) and biomarker tests for dementia will likely be introduced, with potentially significant impacts on community care, particularly general practice. AimTo explore dementia diagnosis, post diagnostic support and expectations around future care in primary care settings. Design and SettingCodesigned survey with general practitioners (GPs), policy researchers, carers and people with lived experience. One GP per practice invited from five of Englands Integrated Care Boards (ICBs). MethodsInductive content analysis for qualitative responses and non-weighted means calculated for quantitative answers. Findings contextualised using national data. ResultsBetween September and December 2025, 80/1094 (7.3%) eligible practices participated (80 GPs). Most, (79/80, 98.8%) used cognitive assessments and 100% (80/80) blood tests to support dementia diagnosis, with 27/70 (39.7%) able to order brain scans directly. GPs primarily conducted annual physical, mental or care plan reviews for people with known dementia. Respondents considered it unlikely (47/80, 58.8%) they would formally diagnose dementia or assess (50/80, 62.3%) for DMT eligibility in the next five years. GPs considered it somewhat/most likely (54/80, 67.5%) they could offer blood biomarker tests and continue established DMT prescribing or monitoring (61/80, 76.3%). Resource, capacity and training needs were perceived barriers. ConclusionGPs are the first point of contact for accessing a dementia diagnosis in England. Accommodating novel diagnostic tools and treatments requires a reimagining of the relationship between primary, secondary and social care to address GP reported constraints.
ER -